The vascular wall is an important endocrine and paracrine organ. Biologically active substances released or present within the wall modulate the properties of the constituent cells. Glandular kallikrein (a kinin- generating enzyme) and its mRNA are present in arteries and veins. Kinins release endothelium-derived factors, which are potent vasodilators and inhibit the growth of vascular smooth muscle cells (VSMC). In addition, they release tissue plasminogen activator (tPA) from endothelial cells and thereby induce fibrinolysis. Our general hypothesis is that the kallikrein-kinin system is an integral component of the vascular wall and is functionally involved in vascular homeostasis. We postulate that vascular kallikrein releases kinins which act at or near their site of formation, contributing to regulation of vascular tone, fibrinolysis and growth.
Our specific aims are:
Aim I : 1) To elucidate the factors regulating kallikrein content and release from arteries and veins; 2) To determine whether kinins are released from vascular tissue; 3) To identify the kininases present in vascular tissue.
Aim II : 1) To determine whether kinin-stimulated release of tPA is mediated by changes in EDRF, and 2) to determine whether increasing endogenous kinins after administration of kininase inhibitors increases plasma fibrinolytic activity.
Aim I V: To determine whether blocking kinins abolishes part of the antiproliferative effect of angiotensin-converting enzyme inhibitors (CEI) following balloon endothelial denudation;
Aim V : To determine whether the vascular kallikrein-kinin system is altered in renovascular, volume-dependent and genetic hypertension. We will measure vascular kallikrein content, kallikrein mRNA and kallikrein release in 2 kidney/1-clip Goldblatt hypertension, DOCA-salt rats and both prehypertensive and hypertensive SHR. These studies will determine whether the vascular kallikrein-kinin system contributes to the regulation of circulatory homeostasis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL028982-15
Application #
5213427
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
15
Fiscal Year
1996
Total Cost
Indirect Cost
Kumar, Nitin; Liao, Tang-Dong; Romero, Cesar A et al. (2018) Thymosin ?4 Deficiency Exacerbates Renal and Cardiac Injury in Angiotensin-II-Induced Hypertension. Hypertension 71:1133-1142
Bryson, Timothy D; Gu, Xiaosong; Khalil, Remonda M et al. (2018) Overexpression of prostaglandin E2 EP4 receptor improves cardiac function after myocardial infarction. J Mol Cell Cardiol 118:1-12
Cerniello, Flavia M; Carretero, Oscar A; Longo Carbajosa, Nadia A et al. (2017) MAS1 Receptor Trafficking Involves ERK1/2 Activation Through a ?-Arrestin2-Dependent Pathway. Hypertension 70:982-989
Ramseyer, Vanesa D; Ortiz, Pablo A; Carretero, Oscar A et al. (2016) Angiotensin II-mediated hypertension impairs nitric oxide-induced NKCC2 inhibition in thick ascending limbs. Am J Physiol Renal Physiol 310:F748-F754
González, Germán E; Rhaleb, N-E; D'Ambrosio, Martin A et al. (2016) Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension. Am J Physiol Heart Circ Physiol 311:H1287-H1296
Gu, Xiaosong; Xu, Jiang; Zhu, Liping et al. (2016) Prostaglandin E2 Reduces Cardiac Contractility via EP3 Receptor. Circ Heart Fail 9:
Kumar, Nitin; Nakagawa, Pablo; Janic, Branislava et al. (2016) The anti-inflammatory peptide Ac-SDKP is released from thymosin-?4 by renal meprin-? and prolyl oligopeptidase. Am J Physiol Renal Physiol 310:F1026-34
Zhu, Liping; Yang, Xiao-Ping; Janic, Branislava et al. (2016) Ac-SDKP suppresses TNF-?-induced ICAM-1 expression in endothelial cells via inhibition of I?B kinase and NF-?B activation. Am J Physiol Heart Circ Physiol 310:H1176-83
Saez, Fara; Hong, Nancy J; Garvin, Jeffrey L (2016) Luminal flow induces NADPH oxidase 4 translocation to the nuclei of thick ascending limbs. Physiol Rep 4:
Cerrato, Bruno D; Carretero, Oscar A; Janic, Brana et al. (2016) Heteromerization Between the Bradykinin B2 Receptor and the Angiotensin-(1-7) Mas Receptor: Functional Consequences. Hypertension 68:1039-48

Showing the most recent 10 out of 381 publications